Screener
Kymera Therapeutics KYMR Finance Lease Liability Noncurrent
Finance Lease Liability Noncurrent at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityNoncurrent.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Non-current liabilities | ||
| Deferred revenue, net of current portion | — | 11,440 |
| Operating lease liabilities, net of current portion | 64,022 | 67,034 |
| Finance lease liabilities, net of current portion | 840 | 1,462 |
| Total liabilities | $136,188 | $163,148 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value; 150,000,000 shares authorized at June 30, 2026 and December 31, 2025, 82,788,253 and 81,323,532 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 8 | 8 |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's finance lease liability noncurrent?
- Kymera Therapeutics (KYMR) reported finance lease liability noncurrent of $840K in Q2 2026.
- How has Kymera Therapeutics's finance lease liability noncurrent changed year-over-year?
- Kymera Therapeutics's finance lease liability noncurrent decreased by 62.0% year-over-year, from $2.21M to $840K.
- What is the long-term trend for Kymera Therapeutics's finance lease liability noncurrent?
- Over 5 years (2020 to 2025), Kymera Therapeutics's finance lease liability noncurrent has grown at a 19.3% compound annual growth rate (CAGR), from $604K to $1.46M.
- What does finance lease liability noncurrent mean?
- Finance Lease Liability Noncurrent as reported by Kymera Therapeutics, Inc. Common Stock.
Ask your AI about Kymera Therapeutics's finance lease liability noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude